US Patent Office Issues Decision to Grant Patent for USMI’s Cold Atmospheric Plasma for the Selective Ablation of Cancer Cells

Jul 24, 2018

TAKOMA PARK, Md.–(BUSINESS WIRE)–US Medical Innovations, LLC (USMI), a U.S. FDA registered life science, biomedical and robotic device company (a subsidiary of US Patent Innovations, LLC), announced today that the United States Patent Office (USPO) has issued USPI patent No. 10,023,858 B2, further expanding its intellectual patent property portfolio for the application of delivering Cold Atmospheric Plasma (CAP) technology to selectively target cancer cells.

Researchers at the Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), Takoma Park, Md., have successfully demonstrated the use of CAP for elevating TRAIL-R1 (Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 1 expression in cancer cells to induce apoptosis.

Dr. Canady (CEO of JCRI-ABTS and USMI) commented, “Breast cancer represents 23% of total cancer cases and 14% of the deaths related to cancers. These cancers are identified by subtypes and the presence or absence of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (HER 2). Patients with HER2 positive breast tumors have the second poorest survival among breast cancer subtypes.”

Utilizing USMI’s patented electrosurgical plasma system, CAP is delivered through the Canady Helios™ Plasma Scalpel, in conjunction with this patented process for elevating a TRAIL-R1 expression in cancer cells, to induce apoptosis. The method entails the steps involved in using electrical energy with a specific voltage, frequency and power from the Cold Plasma Generator (recently issued patent no. 9,999,452 B2) and applying the cold plasma to the surgical margins to target cancer cells. The invention identifies the involvement of a new receptor in plasma medicine, a Tumor Necrosis Factor (TNF) inducing ligand (TRAIL). The TRAIL receptor 1 (TRAIL R-1) activates apoptosis through the death receptors DR4 and DR5. In breast cancer epithelial cells, TRAIL R-1 expression was elevated when treated with CAP while normal breast cells were unaffected.

Dr. Canady additionally commented, “Two decades ago, a humanized monoclonal antibody (mAb) against HER2 was developed and has improved HER2 positive breast cancer patient’s overall survival. Trastuzumab (sold under the brand name Herceptin, a registered trademark of Genentech), is a humanized monoclonal antibody approved by the FDA. Our new patented technology will be an adjunct therapy for treating solid cancerous tumors, especially HER2, Estrogen, Progesterone, and Triple negative receptor breast cancers, as well as promising for those patients who may develop a resistance to Trastuzumab. We plan to begin a multi-center international clinical trial this summer.”

About US Medical Innovations

US Medical Innovations, LLC (USMI), based out of Takoma Park, MD, is a privately-held FDA-registered life science, biomedical and robotic device company. USMI is dedicated to expanding the boundaries of plasma medicine by pioneering new technologies for the development of state-of-the-art medical devices that advance patient outcomes and improve human lives.

US Medical Innovations, LLC (USMI)
Kenniah Chestnut, Esq., 301-270-0147